Fig. 2: Venetoclax (VEN) in combination with artesunate (ART) induce synergistic antileukemia effects in AML cells. | Cell Death & Disease

Fig. 2: Venetoclax (VEN) in combination with artesunate (ART) induce synergistic antileukemia effects in AML cells.

From: Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

Fig. 2

A Growth inhibition of venetoclax or artesunate in five AML cell lines. Cells were treated with venetoclax or artesunate for 72 h. Cell growth inhibition was measured by counting cell number and compared to the untreated group. B Apoptotic cells were determined based on morphological observation using a fluorescence microscope after staining with AO and EB. Cells were treated with venetoclax or artesunate at the indicated concentrations and times. C THP-1 and MOLM-13 cells were treated with venetoclax, artesunate and in combination at the indicated concentrations and times. Apoptotic cells determined by FACS after staining with Annexin V/PI. D Cell cycle distribution assessed by FACS after PI staining. Values are mean ± SD of three independent experiments. **P < 0.01; ***P < 0.001 compared to the control group by t-test. #P < 0.05; ##P < 0.01; ###P < 0.001 by two-way ANOVA test.

Back to article page